Homozygous familial hypercholesterolemia and its treatment by inclisiran

References

• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and european atherosclerosis society (EAS). Europ Heart J. 2020;41:11–188.
   Web of Science ®Google Scholar
• Wong ND, Amsterdam EA, Ballantyne C, et al. For the american society for preventive cardiology. Spotlight from the American society for preventive cardiology on key features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. Am J Cardiovasc Drugs. 2020;20(1):0–0.
   Web of Science ®Google Scholar
• Wilemon KA, Patel J, Aguilar-Salinas C, et al., Reducing the clinical and public health burden of familial hypercholesterolemia a global call to action. JAMA Cardiol. 5(2): 217–229. 2020.
   PubMed Web of Science ®Google Scholar
• Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand. 1938;89:75–84.
   Google Scholar
• Brown MS, Goldstein JL. a receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47.
   PubMed Web of Science ®Google Scholar
• Foody JM, Vishwanath R. Familial hypercholesterolemia/autosomal dominant hypercholesterole mia: molecular defects, the LDL-C continuum, and gradients of phenotypical severity. J Clin Lipidol. 2016;10:970–986.
   PubMed Web of Science ®Google Scholar
• Marais AD. Contrasting effects of sterols on metabolism. J Clin Pathol. 2018;71(10):863–864.
   PubMed Web of Science ®Google Scholar
• Reiss AB, Shah N, Muhieddine D, et al. PCSK9 in cholesterol metabolism: from bench to bedside. Clin Sci. 2018;132:1135–1153.
   PubMed Web of Science ®Google Scholar
• Khademi F, Momtazi-borojeni AA, Reiner Z, et al. PCSK9 and infection: a potentially useful or dangerous association? J Cell Physiol. 2018;233:2920–2927.
   PubMed Web of Science ®Google Scholar
• Paciullo F, Fallarino F, Bianconi V, et al. PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J Cell Physiol. 2017;232:2330–2338.
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Mertikian G, Stahl D, et al. Fatal recurrent staphylococcus aureus infection in a patient with an aortic endostent under alirocumab. Infect Dis Res Treat. 2019;12:1–4.
   Google Scholar
• Ferrari F, Stein R, Motta MT, et al. PCSK9 inhibitors: clinical relevance, molecular mechanisms, and safety in clinical practice. Arq Bra Cardiol. 2019;112(4):453–460.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Tokgozoğlu L, Corsinia a, et al. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis. 2019;288:146–155.
   PubMed Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, et al. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharm. 2019;5:237–245.
   PubMed Web of Science ®Google Scholar
• Tang ZH, Li TH, Peng J, et al. PCSK9: a novel inflammation modulator in atherosclerosis? J Cell Physiol. 2019;234:2345–2355.
   PubMed Web of Science ®Google Scholar
• Angelos D, Karagiannis AD, Liu M, et al. Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors. From molecular biology to clinical translation. Curr Atheroscler Rep. 2018;20:20.
   PubMed Web of Science ®Google Scholar
• Paciullo F, Momi S, Gresele P. PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention. Thromb Haemost. 2019;119:359–367.
   PubMed Web of Science ®Google Scholar
• Filippatosa TD, Christopouloub EC, Elisaf MS. Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors? Curr Opin Lipidol. 2018;29:333–339.
   PubMed Web of Science ®Google Scholar
• Blanchard V, Khantalin I, Ramin-Mangata S, et al., PCSK9: from biology to clinical applications. Pathology. 51(2):177–183. 2019.
   PubMed Web of Science ®Google Scholar
• Glerup S, Schulz R, Laufs U, et al. Physiologic and therapeutic regulation of PCSK9 activity in cardiovascular disease. Basic Res Cardiol. 2017;112:1–23.
   PubMed Web of Science ®Google Scholar
• Amput P, McSweeney C, Palee S, et al. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomed Pharmacother. 2019;109:1171–1180.
   PubMed Web of Science ®Google Scholar
• Schmidt RJ, Zhang Y, Zhao Y, et al. A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol. 2008;27:182–189.
   Web of Science ®Google Scholar
• Gustafsen C, Kjolby M, Nyegaard M, et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 2014;19(2):310–318.
   PubMed Web of Science ®Google Scholar
• Chong M, Yoon G, Susan-Resiga D, et al. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies. J Med Gen. 2020;57:11–17.
   PubMed Web of Science ®Google Scholar
• Malo J, Parajuli a, Walker SM. PCSK9: from molecular biology to clinical applications. Ann Clin Biochem. 2020;57(1):7–25.
   PubMed Web of Science ®Google Scholar
• Fazio S, Minnier J, Shapiro MD, et al. Threshold effects of circulating angiopoietin-like 3 levels on plasma lipoproteins. J Clin Endocrinol Metab. 2017;102(9):3340–3348.
   PubMed Web of Science ®Google Scholar
• Gustafsen C, Olsen D, Vilstrup J, et al. Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nat Commun. 2017;8(1):503.
   PubMedGoogle Scholar
• Kjellmo CA, Hovland a, Lappegård KT. CVD risk stratification in the PCSK9 era: is there a role for LDL subfractions? Diseases. 2018;45:0–0.
   Google Scholar
• Leander K, Mälarstig a, Van’t Hooft FM, et al. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circ. 2016;133:1230–1239.
   PubMed Web of Science ®Google Scholar
• Laugsand LE, Åsvold BO, Vatten LJ, et al. Circulating PCSK9 and risk of myocardial infarction. The HUNT study in norway. J Am Coll Cardiol Bas Transl Sci. 2016;1:568–575.
   Google Scholar
• Xiao Y, Peng C, Huang W, et al. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration and risk of cardiovascular events. systematic review and meta-analysis of prospective studies. Circ J. 2017;81:1150–1157.
   PubMed Web of Science ®Google Scholar
• Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9:e106294.
   PubMed Web of Science ®Google Scholar
• Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117–122.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med. 2006;354:1264–1272.
   PubMed Web of Science ®Google Scholar
• El Khoury P, Elbitar S, Ghaleb Y, et al. PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies. Curr Ath Rep. 2017;19(12):49.
   PubMed Web of Science ®Google Scholar
• Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006;26:1094–1100.
   PubMed Web of Science ®Google Scholar
• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natnl Acad Sci USA. 2003;100(3):928–933.
   PubMed Web of Science ®Google Scholar
• Walley KR, Thain KR, Russell JA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Scie Transl Med. 2014;6:25843.
   Web of Science ®Google Scholar
• Momtazia AA, Banach M, Pirro M, et al. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017;120:157–169.
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17:465.
   PubMed Web of Science ®Google Scholar
• Klein-Szantoa AJP, Bassi DE. Keep recycling going: new approaches to reduce LDL-C. Biochem Pharmacol. 2019;164:336–341.
   PubMed Web of Science ®Google Scholar
• Pettersen D, Fjellström O. Small molecule modulators of PCSK9 – a literature and patent overview. Bioorg Med Chem Lett. 2018;28:1155–1160.
   PubMed Web of Science ®Google Scholar
• Xu S, Luo S, Zhu Z, et al. Small molecules as inhibitors of PCSK9: current status and future challenges. Eur J Med Chem. 2019;162:212e233.
   Web of Science ®Google Scholar
• Lintner NG, McClure KF, Petersen D, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2017;15(3):e2001882.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Tardif JC, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376:1517–1526.
   PubMed Web of Science ®Google Scholar
• Stein E, Toth P, Butcher MB, et al. Safety, tolerability and LDL-C reduction with a novel anti-PCSK9 recombinant fusion protein (LIB003): results of a randomized, double-blind, placebo-controlled, phase 2 study. Abstract European Atherosclerosis Society 87th Congress 2019-1100;287:e7.
   Google Scholar
• Amirfakhryan H. Vaccination against atherosclerosis: an overview. Hell J Cardiol. 2019;S1109-9666: 30125–3.
   Google Scholar
• Weisshaar S, Zeitlinger M. Vaccines targeting PCSK9: a promising alternative to passive immunization with monoclonal antibodies in the management of hyperlipidaemia? Drugs. 2018;78(8):799–808.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhou Y, Pan Y, et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid β-oxidation. J Am Heart Assoc. 2020;9(1):014358.
   Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Nik ME, Jaafari MR, et al. Effects of immunization against PCSK9 in an experimental model of breast cancer. Arch Med Sci. 2019;15(3):570–579.
   PubMed Web of Science ®Google Scholar
• Wang X, Musunuru K. Angiopoietin-like 3 from discovery to therapeutic gene editing. J Am Coll Cardiol Bas Transl Sci. 2019;4:755–762.
   Google Scholar
• Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377:296–297.
   PubMed Web of Science ®Google Scholar
• Gemphire Therapeutics. Gemphire announces interim LDL-C lowering data from COBALT-1 phase 2b clinical trial. News release; 2017 [cited 2020 Jun 12] Available from: https://globenewswire.com/news-release/2017/01/30/911895/0/en/Gemphire-Announces-Interim-LDL-C-Lowering-Data-from-COBALT-1Phase-2b-Clinical-Trial.html
   Google Scholar
• Gaudet D, Durst R, Lepor N, et al. Usefulness of gemcabene in homozygous familial hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019;124:1876–1880.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Raal FJ, Santos RD, et al. Lomitapide and mipomersen—inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Curr Atheroscler Rep. 2019;21:48.
   PubMed Web of Science ®Google Scholar
• Ajufo E, Rader DJ. New therapeutic approaches for familial hypercholesterolemia. Ann Rev Med. 2018;69:113–131.
   PubMed Web of Science ®Google Scholar
• Bernards R. Exploring the uses of RNAi-gene knockdown and the nobel prize. N Engl J Med. 2006;355:2391–2393.
   PubMed Web of Science ®Google Scholar
• German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ghosh GC, Bandyopadhyay D, Ghosh RK, et al. Effectiveness and safety of inclisiran, a novel long-actingRNA therapeutic inhibitor of proprotein convertase subtilisin/kexin9. Am J Cardiol. 2018;122:1272–1277.
   PubMed Web of Science ®Google Scholar
• Raal F, Lepor N, Kallend D, et al. Inclisiran durably lowers LDL-C and PCSK9 expression in subjects with homozygous familial hypercholesterolemia: the Orion-2 pilot study. Circ. 2020;141:1829–1831.
   PubMed Web of Science ®Google Scholar
• A study of inclisiran in participants with homozygous familial hypercholesterolemia (HoFH) (ORION-5). cited 2020 feb 18]. Available from: clinicaltrials.gov/ct2/show/NCT03851705
   Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–1440.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Marais AD. Evolocumab for the treatment of homozygous familial hypercholesterolaemia. Expert Opin Orp Drugs. 2016;4(7):789–798.
   Web of Science ®Google Scholar
• Luirink IK, Wiegman a, Kusters M, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381:1547–1556.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Jun 12] Available from: https://www.gov.uk/government/news/new-heart-disease-drug-to-be- made-available-for-nhs-patients
   Google Scholar
• West R, Gibson P, Lloyd J. Treatment of homozygous familial hypercholesterolaemia: an informative sibship. Brit Med J (Clin Res Ed). 1985;291(6502):1079–1080.
   PubMedGoogle Scholar
• Thompson GR, Blom DJ, Marais AD, et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018;(14):1162–1168. DOI:10.1093/eurheartj/ehx317
   PubMed Web of Science ®Google Scholar
• Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circ. 2002;105(21):2469–2475.
   PubMed Web of Science ®Google Scholar
• Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolaemia. J Lipid Res. 1997;38:2071–2078.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341–350.
   PubMed Web of Science ®Google Scholar
• Sokolov V, Helmlinger G, Nilsson C, et al. Comparative quantitative systems pharmacology modelling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. J Lipid Res. 2019;60:1610–1621.
   PubMed Web of Science ®Google Scholar
• Wang W, Jiang L, Chen PP, et al. a case of sitosterolemia misdiagnosed as familial hypercholesterolemia: a 4-year follow-up. J Clin Lipidol. 2018;12(1):236–239.
   PubMed Web of Science ®Google Scholar
• Muntoni S, Pisciotta L, Muntoni S, et al. Pharmacological treatment of a sardinian patient affected by autosomal recessive hypercholesterolemia (ARH). J Clin Lipidol. 2015;9(1):103–106.
   PubMed Web of Science ®Google Scholar
• D’Erasmo L, Minicocci I, Nicolucci a, et al. Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes. J Am Coll Cardiol. 2018;71(3):279–288. Erratum in: J Am Coll Cardiol 71 (9):1058(2018).
   PubMed Web of Science ®Google Scholar
• Andersen L, Davis T, Testa H, et al. PCSK9 inhibitor therapy in homozygous familial defective apolipoprotein B-100 due to APOB R3500Q: a case report. J Clin Lipidol. 2017;11:1471–1474.
   PubMed Web of Science ®Google Scholar
• Linnik MD, O’Rourke AM, Crowther MA. Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. J Clin Pharmacol. 2008;48:909–918.
   PubMed Web of Science ®Google Scholar
• van de Water FM, Boerman OC, Wouterse AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Disp. 2006;34(8):1393–1397.
   PubMed Web of Science ®Google Scholar
• van Poelgeest EP, Reinout M, Swart RM, et al. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis. 2013;62(4):796–800.
   PubMed Web of Science ®Google Scholar
• Crosby JR, Zhao C, Zhang H, et al. Reversing antisense oligonucleotide activity with a sense oligonucleotide antidote: proof of concept targeting prothrombin. Nucl Acid Ther. 2015;25(6):297–305.
   PubMed Web of Science ®Google Scholar